OncoSec Medical is developing its ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors. Both therapies represent a potential solution for less invasive, less expensive treatments that are able to reduce the damaging effects of currently available cancer treatments. In early and late-stage clinical trials, treatment of various solid cancers using these powerful, targeted anti-cancer therapies has demonstrated selective destruction of cancerous cells while sparing healthy normal tissue. For more information, visit the company’s website at www.oncosec.com.